All In Biotech

Drug Trial Radar · NCT06109415

Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)

A Phase 4, Randomized, Blinded, Active-Controlled Study of HTX-011 in Subjects Undergoing Different Surgical Procedures, Cohort 1: Total Shoulder Arthroplasty (TSA)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Oct 20, 2021

Primary completion

Jul 18, 2022

Study completion Jul 29, 2022

Sponsor

Lead sponsor
Heron TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cohort 1 (subjects undergoing total shoulder arthroplasty, TSA) of a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing different surgical procedures. See also the separate record for the master study protocol (NCT05109312).

Conditions

  • Postoperative Pain
  • Total Shoulder Arthroplasty
  • Multimodal Analgesia

Interventions

  • HTX-011Drug

    HTX-011 (bupivacaine/meloxicam) extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits

  • Bupivacaine HydrochlorideDrug

    bupivacaine HCl (without epinephrine) 0.25%

  • MMA regimenDrug

    acetaminophen 1 g q8h every 8 hours (q8h) and ibuprofen 400 mg q8h, alternating the 2 medications so that an analgesic was taken approximately every 4 hours (q4h)

  • ZYNRELEF kit components for administrationDevice

    ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAEsTime frame: Through Day 15

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland International Research Group, LLC

    Little Rock, Arkansas

  • Center for Orthopaedic Reconstruction and Excellence

    Jenks, Oklahoma

  • First Surgical Hospital

    Bellaire, Texas

  • Legent Orthopedic Hospital

    Carrollton, Texas

  • JBR Clinical Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.